Ghauri Rooha Ijaz, Naveed Muhammad, Mannan Jovaria
Department of Paediatric Medicine, Fatima Memorial Hospital, Lahore.
J Coll Physicians Surg Pak. 2014 Apr;24(4):285-7.
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare, autosomal recessive disorder induced by mutations of the gene coding for thrombopoietin (TPO) receptor (c-MPL) despite high levels of serum TPO. Patients initially present with isolated thrombocytopenia that subsequently progresses into pancytopenia. Although the mechanisms leading to aplasia are unknown, the age of onset has been reported to depend on the severity of the c-MPL functional defect. The primary treatment for CAMT is bone marrow transplantation. This report describes a newborn girl who presented to us with symptoms of sepsis but septic profile came negative except thrombocytopenia. Bone marrow biopsy was done for thrombocytopenia which revealed amegakaryocytic thrombocytopenia. She was given prednisolone.
先天性无巨核细胞性血小板减少症(CAMT)是一种罕见的常染色体隐性疾病,尽管血清血小板生成素(TPO)水平很高,但由于编码TPO受体(c-MPL)的基因突变所致。患者最初表现为单纯性血小板减少症,随后发展为全血细胞减少症。虽然导致再生障碍的机制尚不清楚,但据报道发病年龄取决于c-MPL功能缺陷的严重程度。CAMT的主要治疗方法是骨髓移植。本报告描述了一名新生女婴,她因败血症症状前来就诊,但除血小板减少症外,败血症检查结果为阴性。因血小板减少症进行了骨髓活检,结果显示为无巨核细胞性血小板减少症。她接受了泼尼松龙治疗。